References
- Philips F S, Schwartz H S, Sternberg SS. Pharmacology of mitomycin C: I. Toxicity and pathologic effects. Cancer Res 1960; 20: 1344–1361
- Matsuyama M, Suzumori K, Nakamura T. Biological studies on anticancer agents. I. Effects of prolonged intraperitoneal injections of mitomycin C on the urinary organs. J Urol 1964; 92: 618–620
- Kato T, Nemoto R, Mori H, Kumagai I. Sustained-release properties of microencapsulated mitomycin C with ethylcellulose infused into the renal artery of the dog. Cancer 1980; 46: 14–21
- Cattell V. Mitomycin-induced hemolytic uremic syndrome. An experimental model in the rat. Am J Pathol 1985; 121: 88–95
- Hoyer J R, Mauer S M, Michael AF. Unilateral renal disease in the rat. I. Clinical, morphologic, and glomerular mesangial functional features of the experimental model produced by renal perfusion with aminonucleoside. J Lab Clin Med 1975; 85: 756–768
- Verweij J, Kerpel-Fronius S, Stuurman M, Van Triet A J, Van Hattum L, De Vries J, Pinedo HM. Mitomycin C-induced organ toxicity in Wistar rats: A study with special focus on the kidney. J Cancer Res Clin Oncol 1988; 114: 137–141
- Kuroda K, Teranishi S, Akao M. Toxicity of mitomycin C and anti-intoxication by fumaric acid in liver and kidney cellular fine structure. Gann 1982; 73: 656–660
- Liu K, Mittleman A, Sproul E E, Elias EG. Renal toxicity in man treated with mitomycin C. Cancer 1971; 28: 1314–1320
- Hamner R W, Verani R, Weineman EJ. Mitomycin associated renal failure. Case report and review. Arch Intern Med 1983; 143: 803–807
- Jain S, Seymour AE. Mitomycin C associated hemolytic uremic syndrome. Pathology 1987; 19: 58–61
- Mackintosh J F, Tattersall M HN. Mitomycin-C induced hemolytic-uremic syndrome. Aust NZ J Med 1988; 18: 182–183
- Garibotto G. Successful treatment of mitomycin C-associated hemolytic-uremic syndrome by plasmapheresis. Nephron 1989; 51: 409–413
- Verweij J, Van Der, Burg M EL, Pinedo HM. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drugs. Radiother Oncol 1987; 8: 33–41
- Hanna W T, Krauss S, Regester R F, Murphy WM. Renal disease after mitomycin C therapy. Cancer 1981; 48: 2583–2588
- Koster K T, Boonpucknavig V, Sujaho S, Gilman R H, Rahaman MM. Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clin Nephrol 1984; 21: 126–133
- Scully R E, Mark E J, McNeely W F, McNeely BU. Weekly clini-copathological exercises. N Engl J Med 1988; 318: 1047–1057
- Date A, Raghupathy P, Shastry J CM. Nephron injury in the haemolytic-uraemic syndrome complicating bacillary dysentery. J Pathol 1981; 133: 1–16
- Gianantonio C A, Vitacco M, Mendilaharzu F, Gallo G E, Sojo ET. The hemolytic-uremic syndrome. Nephron 1973; 11: 174–181
- Giroux L, Bettez P, Giroux L. Mitomycin C nephrotoxicity: A clinico-pathologic study of 17 cases. Am J Kidney Dis 1985; 6: 28–39
- Schlager J, Powis G. Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinoneacceptor) oxido-reductase. Cancer Chemother Pharmacol 1988; 22: 126–130
- Eneström S, Druid H, Rammer L. Fibrin deposition in the kidney in post-ischaemic renal damage. Br J Exp Path 1988; 69: 387–394
- Dentino M, Luft F C, Yum M N, Williams S D, Einhorn LH. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978; 41: 1274–1281
- Hall-Craggs M, Brenner D E, Vigorito R D, Sutherland JC. Acute renal failure and renal tubular squamous metaplasia following treatment with streptozotocin. Hum Pathol 1982; 13: 597–602
- Mitra A K, Mailloux AT. Mitomycin C pharmacokinetics in rats-effect of dose size. Int J Pharmaceutics 1986; 32: 133–141
- Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 1985; 55: 47–50
- Nicolson G L, Custead SE. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res 1985; 45: 331–336
- Kvalheim G, Gundersen S, Hager B, Fodstad O. Intra-arterial infusion of mitomycin C in treatment of breast cancer: Occurrence of skin necrosis in irradiated patients. Radiother Oncol 1985; 4: 127–132
- Aizawa H, Tagami H. Delayed tissue necrosis due to mitomycin C. Acta Derm Venereol 1987; 67: 364–366